Home / 2020 / October / 26

Daily Archives: October 26, 2020

Aptean Launches New, First-to-Market Antibody Search Solution to Support Biologics Research and Development

Unique Functionality Now Available within Aptean GenomeQuest, the World’s Leading Intellectual Property Sequence Database

ALPHARETTA, Ga., Oct. 26, 2020 (GLOBE NEWSWIRE) — Today, Aptean, a global provider of mission-critical enterprise software solutions, announced the release of a new solution designed to help companies drastically improve their efficiency in important biologics research and development (R&D). This new tool, the GenomeQuest Antibody Module, is offered through Aptean GenomeQuest, the world’s leading intellectual property (IP) sequence database that combines a comprehensive patent landscape view with the most powerful search, analysis and reporting tools available.

Biologics have landed at the forefront of medical advances in recent years, with antibodies, in particular, being used in increasingly diverse applications, from vaccines to drugs for treating cancer, multiple sclerosis and other autoimmune and common diseases. According to a report by Global Industry Analysts, Inc., the global market for biologics is currently estimated at $292.2 billion and is projected to reach $505.6 billion by 2027—growing at a CAGR of 8.1% over seven years. The antibody treatment trend is unlikely to slow as scientists continue to explore new applications and learn to produce them at scale.

“With the growing focus on antibodies in medicine, it’s critical that companies developing these therapies protect their IP and R&D investments. However, searching for antibody sequences in the intellectual property landscape is notoriously difficult,” said Martin Wagstaff, Aptean’s group vice president of finance and life sciences products. “Searchers typically must perform up to eight separate searches, then spend days painstakingly combining the results to discover potential sequencing alignments. In addition to being deeply inefficient, this makes it challenging to confidently answer critical questions about antibody IP.”

Aptean’s unique GenomeQuest Antibody Module dramatically streamlines the process of antibody sequence search and increases productivity through its user-friendly search interface. Upon query completion, results are displayed in an interactive summary report featuring diagrams that enable users to drill down to patent documents and alignments with extreme ease and accessibility. This new solution provides clear and comprehensive answers to many critical IP questions, delivering more assurance to biologics and large molecule antibody treatment researchers that nothing has been overlooked.

Wagstaff continued, “Our leading IP sequence search database, GenomeQuest, is built upon high-performing proprietary technology, allowing Aptean to add innovations such as streamlined antibody and variation searching into the application. We are proud to be the first company offering this capability to the market and helping our customers protect their valuable investments.”

To learn more about the now available Aptean GenomeQuest Antibody Module, click here.

About Aptean
Aptean is one of the world’s leading providers of industry-specific software. Our enterprise resource planning and supply chain solutions are uniquely designed to meet the needs of specialized manufacturers and distributors in over 20 industries, while our compliance solutions serve specific markets such as finance and life sciences. In total, Aptean’s solutions are used by over 5,000 customers around the world. With both cloud and on-premise deployment options, Aptean’s products, services and unmatched expertise help businesses of all sizes to scale and succeed. Aptean is headquartered in Alpharetta, Georgia and has offices in North America, Europe and Asia-Pacific. To learn more about Aptean and the markets we serve, visit www.aptean.com.

Aptean is a trademark of Aptean, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.

For Media Inquiries Please Contact
Nicole O’Rourke
Chief Marketing Officer
Nicole.Orourke@aptean.com
(770) 715-0362

Taconic Biosciences launches critical model for COVID-19 research

Immediate availability of hACE2 mouse

RENSSELAER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces immediate humanized ACE2 mouse model availability for COVID-19 research.

The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2 receptor to enter cells. Due to differences between the mouse and human ACE2 receptors, normal laboratory mice cannot be infected with SARS-CoV2. Transgenic mice expressing the human ACE2 receptor overcome this challenge and thus are critical for COVID-19 research. Taconic’s hACE2 AC70 mouse model is susceptible to SARS-CoV-2 and displays symptoms upon infection.

Animal models play a vital role in drug discovery, from studying the basic disease characteristics to preclinical safety and efficacy testing. Although SARS-CoV-2 vaccine development is underway, new animal models that address different areas of the drug discovery spectrum are still needed. Global implementation of successful vaccines will take time and may not provide 100% protection against the disease, necessitating continued research on targeted therapeutic options to treat COVID-19 patients. The hACE2 AC70 mouse is valuable because it has utility in both early and late stage drug discovery research. According to a recent Nature article by the members of the World Health Organization expert group on COVID-19 modeling (WHO-COM), “Continued refinement and development of animal models for COVID-19 will contribute to the development of vaccines, therapeutic agents and other countermeasures.”

“It is not enough to create effective animal models, you need to make them readily available,” shared Michael Seiler, vice president of commercial models at Taconic. “Taconic’s experience in global distribution will enable us to get this critical tool into the hands of researchers worldwide. Our current wait list includes researchers from six continents, demonstrating the ongoing demand for COVID-19 animal models.”

Study ready cohorts of animals are available for immediate ordering.

To learn more about hACE2 mice or Taconic’s Coronavirus Toolkit, please contact Taconic Biosciences at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia, and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com

Bombardier Announces Closing Date, Amended Terms for Sale of Aerostructures Business to Spirit AeroSystems Holding, Inc.

  • All closing conditions have been met and the parties have agreed on an October 30, 2020 closing date
  • Total transaction valued at ~ $1.2 billion1; cash proceeds now expected to be $275 million
  • Sale supports Bombardier’s repositioning as a pure-play business jet company and further strengthens liquidity

All amounts in this press release are in U.S. dollars unless otherwise indicated.

MONTREAL, Oct. 26, 2020 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) announced today it has entered into an amended definitive agreement to sell its aerostructures business to Spirit AeroSystems Holding, Inc. (Spirit), supporting Bombardier’s strategic decision to reposition itself as a pure-play business aircraft company. This transaction is set to close on October 30, 2020 as all closing conditions have been met.

Under the amended agreement, Spirit will acquire Bombardier’s aerostructures activities and aftermarket services operations in Belfast, U.K.; Casablanca, Morocco; and its aerostructures maintenance, repair and overhaul (MRO) facility in Dallas, U.S. for cash consideration of $275 million, Spirit’s assumption of liabilities, including government refundable advances and pension obligations, valued at $824 million, as well as certain adjustments to the parties’ trading agreements favourable to Bombardier.

“Today’s announcement marks another milestone towards achieving our strategic goal of repositioning Bombardier as a pure-play business jet company,” said Éric Martel, President and Chief Executive Officer, Bombardier Inc. “We are very excited about our future as a more focused Company. The proceeds from this transaction and from the pending sale of Bombardier Transportation strengthen our liquidity and position us to begin reshaping our capital structure and address our balance sheet challenges so that we can achieve the full potential of our incredibly talented employees and our industry leading business jet portfolio.”

About Bombardier
With nearly 60,000 employees across two business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montréal, Canada, Bombardier has production and engineering sites in over 25 countries across the segments of Aviation and Transportation. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2019, Bombardier posted revenues of $15.8 billion. News and information are available at bombardier.com or follow us on Twitter @Bombardier.

1. Transaction value is based on expected proceeds of $275 million and including Bombardier’s IFRS carrying values as at September 30, 2020 of the transferred liabilities.

Bombardier is a trademark of Bombardier Inc. and its subsidiaries.

For Information
Jessica McDonald
Advisor, Media Relations and Public Affairs
Bombardier Inc.
+1 514 262 7255

Patrick Ghoche
Vice President, Corporate Strategy and Investor Relations
Bombardier Inc.
+514 861 5727

Philips empowers medical image access for over 5,000 clinicians in the Region of Southern Denmark

October 26, 2020

Philips Clinical Collaboration Platform supports telehealth and other connectivity initiatives to increase collaboration across hospitals

Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a regional informatics project that consolidates radiology and nuclear medicine imaging data. The Region of Southern Denmark now has a single system for storing, retrieving, and viewing clinical images across all the locations and specialties in its extensive healthcare system.

The Region of Southern Denmark health service encompasses four hospital groups with a total of 12 hospitals that serve a population of over 1.2 million people living on both on the mainland and the region’s many islands. The unified imaging ecosystem will serve all of the region’s approximately 300 radiologists and nuclear medicine specialists, performing 1.5 million exams yearly. The related images are now accessible to the over 5,000 clinicians in the region.

“Easy access to medical patient data across complex healthcare systems fosters clinical collaboration and is essential to advance precision diagnosis,” said Calum Cunningham, General Manager of Enterprise Diagnostic Informatics at Philips. “We were able to implement our Enterprise Imaging solution in record time, helping the Region of Southern Denmark to move to the next step of digital maturity, improve collaboration, and ultimately enhance patient care.”

“An important requirement was solid integration with the national image registry in Region Sjælland,” said Jørgen Balle Kristensen, Senior IT Project Manager for the Region of Southern Denmark. “The Philips Vendor-Neutral Archive has an open, standards-based design that’s compatible with images in virtually any clinical format, from any source, so it’s a perfect fit for our integration needs.”

The region decided to partner with Philips to advance its digital transformation towards precision diagnosis. The adoption of Philips Enterprise Imaging solutions has started with implementing the Philips Vendor-Neutral Archive (VNA) and Philips Universal Viewer as part of its strategy to replace the existing systems. These modules provide a single source of archiving and distribution of imaging information that enables viewing of clinical images virtually, anytime anywhere by authorized users via a web browser or mobile device.

Philips Enterprise Imaging solutions combine scalable, modular architecture that integrates with existing systems to deliver data and tools across and beyond the enterprise – from radiology data reporting to enterprise-wide ingestion, distribution and archiving, to full patient and clinical data management. It consolidates multiple specialty workstations into a single, multifunctional workspace that allows radiologists to enhance reporting quality. For more information, visit https://www.philips.com/collaboration.

For further information, please contact:

Hans Driessen
Philips Global Press Office
Tel. : +31 6 10610417
E-mail : hans.driessen@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

Philips to nominate Mrs. Indra Nooyi as member of the Supervisory Board

October 26, 2020

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it will propose the appointment of Mrs. Indra Nooyi as a new member of the Supervisory Board to the Annual General Meeting of Shareholders (AGM), which will be held on May 6, 2021.

“We are very pleased to propose Mrs. Indra Nooyi as a new member of Philips’ Supervisory Board,” said Jeroen van der Veer, Chairman of the Supervisory Board of Royal Philips. “She is a proven business leader in the consumer and technology sectors, with a strong track record of delivering sustained profitable growth, while doing business sustainably and responsibly. Her strategic insights will be highly valuable to Philips, as the company embarks on its next growth phase as a health technology leader, with a purpose to improve the health and well-being of people through innovation.”

Mrs. Nooyi (American, 1955) is the former Chair and CEO of PepsiCo, a global food and beverages company with operations in over 180 countries and 2019 sales of USD 67 billion. During her tenure from 2006 till 2019, she was the chief architect of PepsiCo’s ‘Performance with Purpose’ pledge, and successfully delivered sustained growth by making more nutritious products, limiting its environmental footprint, and empowering its associates and people in the communities it serves. Prior to her appointment as CEO, Mrs. Nooyi held various executive leadership positions, including the role of CFO. Before joining PepsiCo in 1994, Mrs. Nooyi held strategy leadership positions at ABB, a leading global technology company, Motorola, a mobile communications pioneer, and the Boston Consulting Group.

For more information about Philips’ Supervisory Board, please follow this link.

For further information, please contact:

Steve Klink
Philips Global Press Office
Tel: +31 6 10888824
E-mail: steve.klink@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

European Markets Nosedive Monday as Global Coronavirus Cases Rise

European markets were falling Monday as investors appeared increasingly uncertain about the outlook of the global economy due to a resurgence of coronavirus cases across Europe and the United States.

Britain’s benchmark FTSE index was down 0.2% at the midway point of the trading day. The CAC-40 index in France lost 0.4%, and Germany’s DAX index plunged 2.2%.

Markets in the Asia-Pacific rim ended mostly lower earlier Monday. Japan’s benchmark Nikkei index finished its trading session down 22 points, but unchanged percentage-wise.

The S&P/ASX index in Australia lost 0.1%. Shanghai’s Composite index was 0.8% lower. South Korea’s KOSPI index dropped 0.7%, while in South Asia, Mumbai’s Sensex plunged 1.3%.

In Hong Kong, the Hang Seng index gained 0.5%, and in Taiwan, the TSEC index finished up 10 points, but was unchanged percentage-wise.

In commodities trading, gold was selling at $1,906.20, up one point. U.S. crude oil was selling at $39.10 per barrel, down 1.8%, and Brent crude was selling at $41.05 per barrel, down 1.7%.

All three major U.S. indices were trending negatively in futures trading as investors awaited the opening bell on Wall Street.

Source: Voice of America

Nigerians Justify Massive Looting of COVID-19 Supplies

ABUJA, NIGERIA – Amid the ongoing protests in Nigeria over police brutality, mobs of citizens have overrun several government-owned warehouses and looted food meant to be distributed during this year’s coronavirus lockdowns. In the latest incident, a mob looted packages of rice, sugar, salt and noodles Monday from a facility in the Nigerian capital.On Saturday, security officials dispersed mobs at another storage facility under attack in Abuja.

Some protesters were demonstrating in front of a facility in Garki, Abuja, as military and police vans barricaded the entrance to the facility.

Earlier, mobs of people trying to attack the facility and make away with some food items were dispersed after security officials fired their guns into the air.

But many, like David Ojo, remained adamant and said they wouldn’t leave until they got some food.

“We need our palliatives. It is our right. My neighbor almost died of hunger because of COVID-19,” said Ojo. “He used to work as security guard at a government institution, but he was sacked. What do you want him to do? I gave him beans and rice, he almost died of hunger.”

Storage facilities holding tons of relief materials have been burglarized and looted in nine states across Nigeria over the last few days.

A private sector coalition against the coronavirus, known as CA-COVID, had collected tens of millions of dollars’ worth of aid for coronavirus victims and given it to the government.

But many state authorities have halted distribution of the aid since the easing of lockdowns.

Some Nigerians accuse authorities of hoarding items while millions of people experience hunger.

Abuja residents like Sunday Chukwu say they didn’t receive any government assistance during lockdowns.

“They didn’t share anything here,” said Chukwu. “Maybe they shared for themselves. But they didn’t share for everybody and these ones now they are hiding it so that people may leave it, they’ll now gather them, they’ll be selling it to the people.”

The coronavirus pandemic exacerbated hunger for many of the country’s extremely poor, who number some 83 million, about 40 percent of the population, according to the country’s statistics bureau.

Vivian Bellonwu, the head of Social Action Nigeria, says the amount of food kept in storage is an indication of “systemic failure.”

“To think that certain persons could lock down this quantum of food and materials as we are seeing them in their premises, in their custody and watching while people wallow in poverty and difficulty, is really unthinkable,” said Bellonwu. “I think that it is quite mean, I think it’s highly insensitive and I think that this is a betrayal of trust of the people.”

The Nigeria Governors’ Forum (NGF) on Monday said the looted items in warehouses in some states were being held for vulnerable people, not hoarded.

As security officials monitor facilities across Nigeria more closely, various state authorities are making plans to commence distribution.

Source: Voice of America